호르몬 치료를 받던 폐경 후 여성에서 발생한 악성 혼합 뮐러종양 1예 = One Case of Malignant Mixed Müllerian Tumor Developed in a Postmenopausal Woman under Hormone Therapy

다국어 초록 (Multilingual Abstract)

Hormone therapy for peri- and postmenopausal women is widely used for relieving vasomotor symptoms or preventing
osteoporosis. Even though exogenous hormone is the most common cause of vaginal bleeding in postmenopausal women
under hormone therapy, in clinical practice, physicians must never exclude the possibility of endometrial disorders, such as
endometrial hyperplasia or cancer. Taking thorough medical history and performing physical and pelvic examinations are
essential for the evaluation of abnormal uterine bleeding in menopausal hormone therapy. Transvaginal ultrasonography,
endometrial aspiration biopsy, dilatation and curettage, and hysteroscopy are the options which physicians may use. This
case is about a woman with continuous combined hormone therapy for 5 years who had experienced rather sudden onset
of vaginal spotting lasting for several months and was fi nally diagnosed as having malignant mixed Müllerian tumor. Our
purpose is to inquire into the proper approaching steps for vaginal bleeding in menopausal hormone therapy

국문 초록 (Abstract)

갱년기 및 폐경기 여성 호르몬 치료는 폐경기 증상의 완화와
골다공증의 예방을 목적으로 광범위하게 사용되고 있다. 호
르몬 요법을 받고 있는 폐경기 여성에서 질 출혈의 가장 흔한
원인은 외인성 호르몬이기는 하지만, 실제 환자 진료 시에는
자궁내막증식증이나 자궁내막암과 같은 자궁내막질환의 가
능성에 대해서도 항상 염두에 두어야 한다. 갱년기 호르몬 치
료에서 나타나는 비정상 자궁 출혈을 평가하기 위해서는 자
세한 병력 청취, 신체 검진 및 골반 검진은 필수사항이며, 이 외
질경유 초음파 검사, 자궁내막 흡인생검, 경관확장 자궁소파
술, 그리고 자궁경 검사 등의 검사법을 통해 도움을 받을 수 있
다. 본 증례는 5년간 지속적 복합호르몬 요법을 받아오던 환자
가 갑작스러운 소량의 파탄성 출혈을 주소로 내원하여, 최적
의 평가 및 검사를 통해 악성혼합 뮐러종양을 진단받은 경우
이다. 저자들은 본 고를 통해 호르몬 치료를 받던 환자에게 비
정상 자궁출혈이 발생하였을 때 고려해야 할 사항들과 그에
따른 적절한 접근 방법 및 단계별 검사의 의미에 대해 고찰함
으로써 일차진료에서의 호르몬 치료에 도움이 되고자 한다.

참고문헌 (Reference)

1 Memarzadeh S, Mundt AJ, Plaxe SC, "Uterine carcinosarcoma" UpToDate, Inc.

2 Korea Statistical Information Service, "The life table" Korea National Statistical Office

3 Goodman A, "The evaluation and management of uterine bleeding in postmenopausal women" UpToDate, Inc.

4 Kim JG, "The Korean Society of Menopause: Management of menopausal women. 2nd ed" KoonJa 2001

5 National Cancer Institute, "SEER survival monograph" US National Institute of Health

6 Rossouw JE, "Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause" 297 : 1465-1477, 2007

7 Guido RS, "Pipelle endometrial sampling. Sensitivity in the detection of endometrial cancer" 40 : 553-555, 1995

8 Yamada SD, "Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus" 88 : 2782-2786, 2000

9 MacMahon B, "Overview of studies on endometrial cancer and other types of cancer in humans: perspectives of an epidemiologist" 24 (24): S122-S139, 1997

10 Hersh AL, "National use of postmenopausal hormone therapy: annual trends and response to recent evidence" 291 : 47-53, 2004

11 Callister M, "Malignant mixed Mullerian tumors of the uterus: analysis of patt erns of failure, prognostic factors, and treatment outcome" 58 : 786-796, 2004

12 Chlebowski RT, "Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women:the Women's Health Initiative Randomized Trial" 289 : 3243-3253, 2003

13 Lethaby A, "Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding" (3) : CD000402-, 2004

14 Belchetz PE, "Hormonal treatment of postmenopausal women" 330 : 1062-1071, 1994

15 Schwartz SM, "Exogenous sex hormone use, correlates of endogenous hormone levels, and the incidence of histologic types of sarcoma of the uterus" 77 : 717-724, 1996

16 Zelmanowicz A, "Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors" 69 : 253-257, 1998

17 Feldman S, "Evaluation of the endometrium for malignant or premalignant disease" UpToDate, Inc.

18 Manson JE, "Estrogen plus progestin and the risk of coronary heart disease" 349 : 523-534, 2003

19 "Estrogen and progestogen use in peri-and postmenopausal women: March 2007 position statement of The North American Menopause Society" 14 : 168-182, 2007

20 Stovall TG, "Endometrial sampling prior to hysterectomy" 73 : 405-409, 1989

21 Wassertheil-Smoller S, "Effect of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: a randomized trial" 289 : 2673-2684, 2003

22 Grimes DA, "Diagnostic dilation and curett age: a reappraisal" 142 : 1-6, 1982

23 Archer DF, "Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate: Menopause Study Group" 83 : 686-692, 1994

24 Berek JS, "Berek & Novak's gynecology. 14th ed" Lippincott Williams & Wilkins 2007

25 Kang BM, "Attitudes of Korean clinicians to postmenopausal hormone therapy after the Women's Health Initiative study" 13 : 125-129, 2006

26 Lipscomb GH, "A randomized comparison of the Pipelle, Accurette, and Explora endometrial sampling devices" 170 : 591-594, 1994